← Eichor
Study identifier: NCT03216525 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Condition: Bladder Cancer  ·  Sponsor: Brigham and Women's Hospital

PhasePhase 3
Planned participants136
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Martin Barylak  ·  6175258274  ·  mbarylak@bwh.harvard.edu

Anjali Vasavada  ·  6175258274  ·  AVASAVADA@BWH.HARVARD.EDU

Always discuss trial participation with your own doctor first.

Locations (1)

Brigham and Women's HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03216525